CONSTRUCTION COMMENCES AT MODERNA INNOVATION AND TECHNOLOGY CENTRE IN THE UK
Construction of Moderna’s research, development and manufacturing facility has begun, with groundbroken on the facility’s site at the Harwell Science and Innovation Campus, Oxfordshire
Facility to provide UK public with access to domestically manufactured mRNA respiratory vaccines,
pending assessment and licensure
UK site being built to deliver Moderna’s ten-year strategic partnership with the UK government
LONDON, UK.—(ACCESS WIRE)— 25 April, 2023—Moderna, Inc. (Nasdaq: MRNA), a biotechnology
company pioneering messenger RNA (mRNA) therapeutics and vaccines, today commenced
construction of its Moderna Innovation and Technology Centre (MITC) in Harwell, Oxfordshire. TheMITC will encompass research, development and a manufacturing facility, which aims to provide theUK public with access to mRNA vaccines for a wide range of respiratory diseases, pending independent
regulatory assessment and licensure.
Darius Hughes, UK General Manager at Moderna, said: “We are delighted to celebrate this importantmilestone today alongside our partners from the UK Government and Harwell. We look forward tocontinuing our collaboration throughout construction of the Moderna Innovation and Technology
Centre, and beyond, to bring innovative vaccines to the UK public to help protect against emerging
respiratory health threats.”
A ground breaking ceremony was attended by Dame Jenny Harries, local community leaders andrepresentatives from the UK’s health resilience and life sciences community.
The Moderna investment will create hundreds of jobs during construction and operation. The MITC
will include a clinical biomarker laboratory that will be constructed by the offsite construction andengineering specialist Merit. The Drug Substance and Manufacturing facility will be fitted out by
Birmingham-based engineering firm IPS and is expected to become operational in 2025.
Attributable quotes
Health Minister Maria Caulfield, said: “Thanks to this partnership between the government andModerna, NHS patients across the country will have access to cutting edge mRNA vaccines to fight
future Covid variants and other respiratory viruses, so it’s great to see construction starting on thisnew centre.
“Putting spades in the ground in Harwell also marks a new chapter in the country’s pandemic
preparedness as up to 250 million vaccines per year will be produced here – helping to keep the UK
population safe in the event of a future pandemic.”
Professor Dame Jenny Harries, chief executive of the UK Health Security Agency, said: “This facility
will significantly strengthen the UK’s vaccine development and research capabilities, helping shore
up our defences against future health threats, including pandemics.
“Once built, it will be capable of producing millions of vaccines against respiratory diseases andother illnesses, placing the UK at the global forefront of health science and innovation.
“Partnerships like the one we have with Moderna will help us remain agile in our response to healththreats as they emerge, and the construction of this facility will help ensure the UK has a healthprotection system fit for the future.”
Stuart Grant, Chief Executive of Harwell Campus said: “Starting construction of the Moderna
Innovation and Technology Centre is an important milestone for the campus. It signifies the growing
depth and breadth of innovative research into mRNA and nucleic acid therapeutics that is taking place
at Harwell. We’re looking forward to working closely with Moderna to help them build connections
and collaborations across our flourishing Health Tech cluster.”
ENDS
Notes to editors:
About Moderna
In over 10 years since its inception, Moderna (known in the UK as Moderna Biotech UK) has
transformed from a science research-stage company advancing programs in the field of messenger
RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics acrossseven modalities, a broad intellectual property portfolio and integrated manufacturing facilities thatallow for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad
range of domestic and overseas government and commercial collaborators, which has allowed for thepursuit of both ground-breaking science and rapid scaling of manufacturing. Most recently, Moderna's
capabilities have come together to allow the authorized use of effective vaccines against the COVID19 pandemic.
Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science,delivery technology and manufacturing, and has allowed the development of therapeutics andvaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. To learn more, visit www.modernatx.co.uk
Harwell Science and Innovation Campus
Harwell is the UK's leading science and innovation campus, where government, academia and industry
work together to solve the critical problems facing our planet. The campus is home to £3bn national
facilities and 6,000 colleagues committed to scientific discovery and understanding.
Moderna is the latest organisation to join Harwell’s thriving Health Tech cluster which has grown toover 70 life science organisations since it launched in 2016.
The campus’ unique combination of expertise in the development of vaccines and mRNA technologies
includes: Europe’s largest collection of open access, publicly funded scientific facilities, such as The
Rosalind Franklin Institute and the Nucleic Acid Therapy Accelerator and commercial organisations
including: Catalent, Vaccitech, NeoVac and Nanovation Therapeutics.
Harwell is managed and developed by a joint venture between the Science and Technology Facilities
Council, the UK Atomic Energy Authority and the private sector investor, Brookfield.
Follow us on twitter and LinkedIn @HarwellCampus, or learn more here www.harwellcampus.com
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995, as amended, including regarding: construction of the Moderna
Innovation and Technology Centre and Moderna’s ten-year strategic partnership with the UK
government; Moderna’s aim for the facility to provide the UK public with access to domesticallymanufactured mRNA respiratory vaccines, pending assessment and licensure; the anticipatedcreation of jobs during construction and operation of the facility; and expected timing for the Drug
Substance and Manufacturing facility to become operational. The forward-looking statements in thispress release are neither promises nor guarantees, and you should not place undue reliance onthese forward-looking statements because they involve known and unknown risks, uncertainties,
and other factors, many of which are beyond Moderna’s control and which could cause actual
results to differ materially from those expressed or implied by these forward-looking statements.
These risks, uncertainties, and other factors include those other risks and uncertainties describedunder the heading “Risk Factors” in Moderna’s Annual Report on Form 10-K for the year ended
December 31, 2022, filed with the U.S. Securities and Exchange Commission (SEC), and in
subsequent filings made by Moderna with the SEC, which are available on the SEC’s website atwww.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for
updating or revising any forward-looking statements contained in this press release in the event of
new information, future developments or otherwise. These forward-looking statements are basedon Moderna’s current expectations and speak only as of the date of this press release.
Moderna contacts
Media:
Emma Gilgunn-Jones
UK Director of Communications
emma.gilgunn-jones@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
617-209-5834
Lavina.Talukdar@modernatx.com

Harwell contact
Dan Metcalfe
Director of Communications
dan.metcalfe@harwellcampus.com
SOURCE: Moderna, Inc.